Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Debiopharm S.A.
Transactions involving Biocon/Zentiva, CrystalGenomics/PanGen, Umoja/IASO, Marinus/Tenacia, Ono/Captor and Daewoong/HitGen plus deals in brief.
Full-Life’s acquisition of Focus-X came after two other Chinese biotechs leaped into the fray for a leading position in China’s nascent radionuclide therapy market.
The German group says that 50% of future new launches are expected to come from externally sourced assets to take the strain of its organic discovery engine.
During Q3, biopharma merger and acquisition value reached $15.4bn and drew in $37.6bn in potential deal value from alliances. Device company M&A values reached $550m, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $1.9bn.
- Drug Delivery
- Other Names / Subsidiaries
- H3 Pharma
- Affinium Pharmaceuticals, Ltd.